X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ALEMBIC LTD - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE ALEMBIC LTD CADILA HEALTHCARE/
ALEMBIC LTD
 
P/E (TTM) x 20.3 61.0 33.3% View Chart
P/BV x 4.8 2.5 189.0% View Chart
Dividend Yield % 0.9 0.4 212.5%  

Financials

 CADILA HEALTHCARE   ALEMBIC LTD
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
ALEMBIC LTD
Mar-18
CADILA HEALTHCARE/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs55872 775.0%   
Low Rs36234 1,066.4%   
Sales per share (Unadj.) Rs116.34.7 2,473.9%  
Earnings per share (Unadj.) Rs17.96.1 292.7%  
Cash flow per share (Unadj.) Rs23.16.2 370.4%  
Dividends per share (Unadj.) Rs3.500.20 1,750.0%  
Dividend yield (eoy) %0.80.4 201.5%  
Book value per share (Unadj.) Rs85.440.7 210.1%  
Shares outstanding (eoy) m1,023.74267.03 383.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.011.3 35.1%   
Avg P/E ratio x25.78.7 296.6%  
P/CF ratio (eoy) x19.98.5 234.4%  
Price / Book Value ratio x5.41.3 413.3%  
Dividend payout %19.63.3 597.8%   
Avg Mkt Cap Rs m470,66414,139 3,328.8%   
No. of employees `00011.8NA-   
Total wages/salary Rs m18,545207 8,941.7%   
Avg. sales/employee Rs Th10,072.7NM-  
Avg. wages/employee Rs Th1,569.1NM-  
Avg. net profit/employee Rs Th1,547.7NM-  
INCOME DATA
Net Sales Rs m119,0491,255 9,484.5%  
Other income Rs m1,132370 305.8%   
Total revenues Rs m120,1811,625 7,393.9%   
Gross profit Rs m28,475111 25,630.1%  
Depreciation Rs m5,38838 14,254.0%   
Interest Rs m9112 53,588.2%   
Profit before tax Rs m23,308442 5,275.7%   
Minority Interest Rs m6280-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,64424 23,565.8%   
Profit after tax Rs m18,2921,630 1,122.3%  
Gross profit margin %23.98.9 270.2%  
Effective tax rate %24.25.4 446.7%   
Net profit margin %15.4129.8 11.8%  
BALANCE SHEET DATA
Current assets Rs m82,0051,867 4,392.1%   
Current liabilities Rs m60,720591 10,270.6%   
Net working cap to sales %17.9101.6 17.6%  
Current ratio x1.43.2 42.8%  
Inventory Days Days7394 77.6%  
Debtors Days Days9874 133.7%  
Net fixed assets Rs m83,7031,791 4,673.8%   
Share capital Rs m1,024534 191.7%   
"Free" reserves Rs m86,42110,324 837.1%   
Net worth Rs m87,44510,858 805.4%   
Long term debt Rs m25,55141 62,017.0%   
Total assets Rs m180,65311,591 1,558.6%  
Interest coverage x26.6260.9 10.2%   
Debt to equity ratio x0.30 7,700.4%  
Sales to assets ratio x0.70.1 608.5%   
Return on assets %10.614.1 75.5%  
Return on equity %20.915.0 139.4%  
Return on capital %22.015.2 144.8%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m42,68319 220,015.5%   
Fx outflow Rs m11,242264 4,261.2%   
Net fx Rs m31,441-244 -12,863.5%   
CASH FLOW
From Operations Rs m9,193236 3,898.6%  
From Investments Rs m-9,737-224 4,346.9%  
From Financial Activity Rs m515-27 -1,936.1%  
Net Cashflow Rs m-29-15 195.9%  

Share Holding

Indian Promoters % 74.8 64.0 116.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.2 4,150.0%  
FIIs % 5.9 9.7 60.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 26.1 42.1%  
Shareholders   44,069 54,701 80.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Healthcare & Metal Stocks Gain(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.5% while the Hang Seng is up 1.2%.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 19, 2018 10:09 AM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS